Abstract
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
